RxDoctor Payments Data

David Yao, MD

Urology · Santa Monica, CANPI 1831269851

Payments from drug & device makers

$3,100in general payments, 2019–2025

Across 70 payments — averaging $44.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$2K
  • AbbVie$565
  • C. R. Bard, Inc. & Subsidiaries$411
  • Rochester Medical Corporation$84
  • BD$65
  • Astellas Pharma US Inc$65
  • plus $307 from 10 others

What the payments were for

  • Grants$1,58151%
  • Food & beverage$1,45447%
  • Education$652%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Boston Scientific2$1,603
AbbVie26$565
C. R. Bard, Inc. & Subsidiaries19$411
Rochester Medical Corporation5$84
BD3$65
Astellas Pharma US Inc1$65
Progenics Pharmaceuticals, Inc.3$54
Sumitomo Pharma America, Inc.2$47
Coloplast2$38
Axonics, Inc.1$33
180 Medical, Inc.1$27
Teleflex LLC1$27
Mentor Worldwide LLC1$25
Urogen Pharma, Inc.1$25
Verity Pharmaceuticals Inc.1$18
Zyla Life Sciences, Inc.1$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,100 in reported general payments places this provider in the 50th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$233,926
Medicare patients
686
Services billed
6,602

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron180$174,211
GemtesaVibegron158$140,267
Tamsulosin Hcl790$17,017
Testosterone15$16,897
Trospium Chloride205$15,027
Tadalafil98$12,860
Methenamine Hippurate118$10,773
Alfuzosin Hcl ErAlfuzosin Hcl319$10,732
Trospium Chloride ErTrospium Chloride25$8,180
Finasteride307$5,106
Potassium Citrate ErPotassium Citrate32$4,412
Silodosin27$3,701
Testosterone Cypionate66$3,573
Dutasteride48$1,961
Desmopressin Acetate13$1,471

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$65$174,211180 claims
Sumitomo Pharma America, Inc.Gemtesa$47$140,267158 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 1,324 urology providers in California.

Other urology in Santa Monica

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →